DC-based vaccines induce the activity of CTLs expressing low levels of CTLA-4 and PD-1 to increase their cytolytic ability and to enhance the expression of different molecules (CXCR3 and CD103/CD49a) to empower the migration of CTLs towards the tumor microenvironment [157]. The gene discussed is PDCD1; the disease is neoplasm.